Significant reductions in body weight are observed with 3.0 mg and 4.5 mg dulaglutide, doses which have been recently approved for people living with T2DM who are taking metformin but experiencing inadequate glycemic control [66, 119]
As demand for advanced peptide therapies grows, clinicians must rely on rigorous, evidence-based education to ensure safe and effective integration.
Id been dealing with tendinitis for a year, he remembers, but it had been extreme for about six months
Of importance, experimental studies have suggested that several GLP-1 RAs can cross the bloodbrain barrier, at least at some extent, upon systemic administration [46,47]
Slower dose titration or temporary dose reduction may be appropriate if symptoms are severe